CC-5013: Treatment of multiple myeloma treatment of melanoma treatment of myelodysplastic syndrome angiogenesis inhibitor TNF-α production inhibitor

Drugs of the Future

Volumn 28, Issue 5, 2003, Pages 425-431

  Sorbera, L A ^a   Castaner J ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE TETRAMETHYLENEPHOSPHONIC ACID HO 166; 2 METHOXYESTRADIOL; 3 (4 AMINO 1 OXO 1,3 DIHYDRO 2H ISOINDOL 2 YL)PIPERIDINE 2,6 DIONE; 3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 6 O BENZYLGUANINE; AE 941; ALVOCODIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ATLIZUMAB; BETA ALETHINE; BORTEZOMIB; BREVAREX; DEXAMETHASONE; DOXORUBICIN; ENMD 0995; GALLIUM MALTOLATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYPNOTIC SEDATIVE AGENT; IMID 3; LENALIDOMIDE; LYMPHORAD; LYMPHORAD 131; MINODRONIC ACID; NAVELBINE; OBLIMERSEN; PI 88; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND R1 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ADVANCED CANCER; ANTIEMETIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CYCLIZATION; CYTOKINE PRODUCTION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; INHIBITION KINETICS; MELANOMA; MULTIPLE MYELOMA; MUSCLE CRAMP; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RASH; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; STEADY STATE; SURVIVAL RATE; SYNCOPE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0041471664     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.05.734386     Document Type: Article

References (38)

1. Muller, G.W., Stirling, D.I., Chen, R.S.-C. (Celgene Corp.). Substd. 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNFα levels. EP 0925294, US 5635517, WO 9803502.
2. Muller, G.W., Chen, R., Huang, S.Y., Corral, L.G., Wong, L.M., Patterson, R.T., Chen, Y., Kaplan, G., Stirling, D.I. Amino substituted thalidomide analogs: Potent inhibitors of TNF-α production. Bioorg Med Chem Lett 1999, 9: 1625-30.
3. Botting, J. The history of thalidomide. Drug News Perspect 2002, 15: 604-11.
4. Sommer, C. Thalidomide as a blocker of TNF production. Drugs Fut 1999, 24: 67-75.
5. Mellin, G., Katzenstein, M. The saga of thalidomide. New Engl J Med 1962, 267: 1184-93.
6. Fullerton, P.M., Kremer, M. Neuropathy after intake of thalidomide. BMJ - Br Med J 1961, 2: 855-8.
7. Pfeiffer, R.A., Kosenow, W. Thalidomide and congenital abnormalities. Lancet 1962, 1: 45.
8. Sheskin, J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965, 6: 303-6.
9. Barnhill, R., McDougall, A. Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol 1982, 7: 317-23.
10. Sarno, E.N., Grau, G.E., Vieira, L.M., Nery, J.A. Serum levels of tumour necrosis factor-α and interleukin-1β during leprosy reactional states. Clin Exp Immunol 1991, 84: 103-8.
11. Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A., Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 1991, 173: 699-703.
12. Barnes, P.F., Chatterjee, D., Brennan, P.J., Rea, T.H., Modlin, R.L. Tumor necrosis factor production in patients with leprosy. Infect Immun 1992, 60: 1441-6.
13. Marriott, J.B., Muller, G., Dalgleish, A.G. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999, 20: 538-40.
14. Raje, N., Anderson, K. Thalidomide - a revival story. New Engl J Med 1999, 341: 1606-9.
15. + subset. J Exp Med 1998, 187: 1885-92.
16. Singhal, S., Mehta, J., Desikan, R. et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 1999, 341: 1565-71.
17. Barlogie, B., Desikan, R., Eddlemon, P. et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98: 492-4.
18. Neben, K., Moehler, T.M., Benner, A., Kraemer, A., Ho, A.D., Goldschmidt, H. Dose-dependent effect of thalidomide (THAL) on overall survival (OS) in relapsed and refractory multiple myeloma (MM). Blood 2001, 98(11, Part 1): Abst 690.
19. Corral, L.G., Haslett, P.A., Muller, G.W., Chen, R., Wong, L.-M., Ocampo, C.J., Patterson, R.T., Stirling, D.I., Kaplan, G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999, 163: 380-6.
20. Moreira, A.L., Corral, L.G., Ye, W., Johnson, B., Stirling, D., Muller, G.W., Freedman, V.H., Kaplan, G. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses 1997, 13: 857-63.
21. + T cells. Clin Exp Immunol 2002, 130: 75-84.
22. Dredge, K., Marriott, J.B., Macdonald, C.D., Man, H.-W., Chen, R., Muller, G.W., Stirling, D., Dalgleish, A.G. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002, 87: 1166-72.
23. List, A.F., Tate, W., Glinsmann-Gibson, B.J., Baker, A. The immunomodulatory thalidomide analog, CC5013, inhibits trophic response to VEGF in AML cells by abolishing cytokine-induced PI3-kinase/Akt activation. Blood 2002, 100(11, Part 1): Abst 521.
24. Hayashi, T., Hideshima, T., Akiyama, M., Munshi, N., Chaudhan, D., Anderson, K.C. Mechanisms whereby immunomodulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity. Blood 2002, 100(11, Part 1): Abst 3219.
25. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N.C., Treon, S.P., Anderson, K.C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002, 99: 4525-30.
26. Tsenova, L., Mangaliso, B., Muller, G., Chen, Y., Freedman, V.H., Stirling, D., Kaplan, G. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. Antimicrob Agents Chemother 2002, 46: 1887-95.
27. Scheffler, M.R., Thomas, S., Harden, J., Oliver, S.D., Teo, S.K. Safety and pharmacokinetics of CDC-501, a novel immunomodulatory-oncologic agent, after single then multiple, oral 100 mg twice daily doses. Clin Pharmacol Ther 2002, 71(2): Abst WPIII-63.
28. Teo, S.K., Oliver, S., Harden, J., Stirling, D., Thomas, S., Scheffler, M. A phase I, single-blind, placebo-controlled, ascending single oral dose, safety, tolerability and pharmacokinetic study of CDC-501, a novel immunomodulatory-oncologic agent, in healthy male subjects with a comparison of fed and fasted. Clin Pharmacol Ther 2002, 71(2): Abst WPIII-64.
29. Zangari, M., Tricot, G., Zeldis, J., Eddlemon, P., Saghafifar, F., Barlogie, B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapsed after high dose chemotherapy (HDCT). Blood 2001, 98(11, Part 1): Abst 3226.
30. Richardson, P.G., Schlossman, R.L., Weller, E. et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100: 3063-7.
31. Marriott, J.B., Clarke, I.A., Dredge, K., Pandha, H., Kristaleit, H., Polychronis, A., Muller, G.W., Stirling, D., Dalgleish, A.G. Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation. Br J Cancer 2002, 86(Suppl. 1): Abst 6.4.
32. Richardson, P., Jagannath, S., Schlossman, R. et al. A multicenter, randomized, phase II study to evaluate the efficacy and safety of two CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM). Blood 2002, 100(11, Part 1): Abst 386.
33. Revimid™ monotherapy induces reduction or stabilization of paraprotein levels in eighty-five percent of advanced multiple myeloma patients in phase II trial. Celgene Corp. Press Release December 9, 2002.
34. Revimid granted fast track designation for relapsed or refractory multiple myeloma. DailyDrugNews.com (Daily Essentials) February 6, 2003.
35. List, A.F., Kurtin, S.E., Glinsmann-Gibson, B.J., Bellamy, W.T., Buresh, A.J., Waddleton, D., Knight, R. High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS). Blood 2002, 100(11, Part 1): Abst 353.
36. First data on Revimid™ in myelodysplastic syndromes demonstrates fifty-six percent of patients achieved hematological response. Celgene Corp. Press Release December 10, 2002.
37. Revimid granted fast track status for myelodysplastic syndromes. DailyDrugNews.com (Daily Essentials) April 17, 2003.
38. Celgene summarizes recent clinical development highlights. DailyDrugNews.com (Daily Essentials) January 10, 2003.